Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period, six-sequence crossover study

Abstract

Huperzine A is a potent, reversible, and blood-brain barrier permeable acetylcholinesterase inhibitor. The aim of this study was to compare the pharmacokinetics, tolerability, and bioavailability of two formulations with the established reference formulation of huperzine A in a fasting, healthy Chinese male population. This was a randomized, single-dose, 3-period, 6-sequence crossover study. The plasma concentrations of huperzine A were determined by liquid chromatography tandem mass spectrometry. Tolerability was assessed based on subject interview, vital sign monitoring, physical examination, and routine blood and urine tests. The mean (SD) pharmacokinetic parameters of the reference drug were C_max, 1.550 (0.528) ng/mL; t_1/2, 12.092 (1.898) h; AUC_0-72h, 17.550 (3.794) ng·h/mL. Those of the test formulation A and test formulation B were C_max, 1.412 (0.467), 1.521 (0.608) ng/mL; t_1/2, 12.073 (2.068), 12.271 (1.678) h; AUC_0-72h, 15.286 (3.434) ng·h/mL, 15.673 (3.586) ng·h/mL. The 90% confidence intervals for the AUC_0-72h and C_max were between 0.80 and 1.25. No adverse events were reported by the subjects or found with results of clinical laboratory test. The test and reference products met the regulatory criteria for bioequivalence in these fasting, healthy Chinese male volunteers. All three formulations appeared to be well tolerated.

Keywords

huperzine A / pharmacokinetics / bioequivalence / tolerability / liquid chromatography tandem mass spectrometry

References

[1] WangR, YanH, TangXC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta pharmacol Sin, 2006, 27(1): 1-26 PMID: 16364207

[2] YeJC, ZengS, ZhengGL, et al. . Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm, 2008, 356(1-2): 187-92 PMID: 18289810

[3] ChuDF, FuXQ, LiuWH, et al. . Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm, 2006, 325(1-2): 116-123 PMID: 16876971

[4] ColemanBR, RatcliffeRH, OguntayoSA, et al. . [+]-Huperzine A treatment protects against N-methyl-Daspartate-induced seizure/status epilepticus in rats. Chem Biol Interact, 2008, 175(1-3): 387-395 PMID: 18588864

[5] ZhangZ, WangX, ChenQ, et al. . Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yixue Zazhi (Chinese), 2002, 82(14): 941-944

[6] MaX, TanC, ZhuD, et al. . Huperzine A from Huperzia species—an ethnopharmacolgical review. J Ethnopharmacol, 2007, 113(1): 15-34 PMID: 17644292

[7] US National Institutes of Health. Huperzine A in Alzheimer's Disease. http://clinicaltrialsgov/ct2/show/ NCT00083590

[8] US National Institutes of Health. Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance. http://clinicaltrials.gov/ct2/show/NCT01194336

[9] HaydenC. A generic solution?: pharmaceuticals and the politics of the similar in Mexico. Curr Anthropol, 2007, 48(4): 475-495

[10] US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and bioequivalence studies for orally administered durg products-general considerations. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm154838.pdf

[11] State Food and Drug Administration. Guideline for bioavailability and bioequivalence studies of generic drug products (Chinese). http://www.sda.gov.cn/gsz05106/08.pdf

[12] JiangB, RuanZ, ChenJ, et al. . Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. Drug Dev Ind Pharm, 2016, 42(9): 1476-1481 PMID: 26850676

[13] LiewKB, PehKK, LohGO, et al. . Three-ways crossover bioequivalence study of cephalexin in healthy Malay volunteers. Drug Dev Ind Pharm, 2014, 40(9): 1156-1162 PMID: 23688276

[14] LiYX, ZhangRQ, LiCR, et al. . Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet, 2007, 32(4): 183-187 PMID: 18348466

[15] QianBC, WangM, ZhouZF, et al. . Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin, 1995, 16(5): 396-398

[16] LiW, LiJ, HuQ. Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. Biomed Chromatogr, 2008, 22(4): 354-360 PMID: 17939152

[17] Code of Federal Regulations, Title 21, Part 320. Bioavailabilty and bioequivalence requirements. US Food and Drug Administration Web site. April 2010. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfr search.cfm?cfrpart=320

[18] ShiS, LiuY, WuJ, et al. . Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. Clin Ther, 2010, 32(11): 1977-1986 PMID: 21095492

[19] LiC, DuF, YuC, et al. . A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom, 2004, 18(6): 651-656 PMID: 15052575

[20] YueP, TaoT, ZhaoY, et al. . Determination of Huperzine A in rat plasma by high-performance liquid chromatography with a fluorescence detector. J Pharm Biomed Anal, 2007, 44(1): 309-312 PMID: 17408901

[21] YueP, TaoT, ZhaoY, et al. . Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm, 2007, 337(1-2): 127-132 PMID: 17241758

[22] XuSS, CaiZY, QuZW, et al. . Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacol Sin, 1999, 20(6): 486-490

[23] IqbalM, KhurooA, BatolarLS, et al. . Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin Ther, 2010, 32(3): 588-596 PMID: 20399995

[24] CritchleyDJ, AluriJ, BoydP, et al. . Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects. Clin Ther, 2011, 33(1): 146-157 PMID: 21397780